Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin

This article was originally published in The Pink Sheet Daily

Executive Summary

Telavancin NDA for nosocomial pneumonia on hold as FDA asks for more mortality data while it assesses new requirements for HAP antibiotics.

You may also be interested in...



Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.

Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn

The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.

Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn

The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel